Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry
Date
2019-01-21Author
Kalyoncu, Umut
Kiraz, Sedat
Apras Bilgen, Sule
Karadağ, Ömer
Akdoğan, Ali
Kılıç, Levent
Erden, Abdulsamet
Armagan, Berkan
Sari, Alper
Ertenli, İhsan
xmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Objective
Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment.
Methods
We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response.
Results
Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments.
Conclusion
A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments.
URI
http://hdl.handle.net/11655/23566https://doi.org/10.1007/s10067-019-04426-3
https://pubmed.ncbi.nlm.nih.gov/30663017/
xmlui.mirage2.itemSummaryView.Collections
xmlui.dri2xhtml.METS-1.0.item-citation
Kalyoncu U, Kiraz S, Bilgen SA, Karadag O, Akdogan A, Kilic L, Erden A, Armagan B, Sari A, Ertenli I. Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clin Rheumatol. 2019 Apr;38(4):1187-1192. doi: 10.1007/s10067-019-04426-3. Epub 2019 Jan 21. PMID: 30663017.The following license files are associated with this item: